154 related articles for article (PubMed ID: 14603076)
1. An overview of proton pump inhibitors.
Der G
Gastroenterol Nurs; 2003; 26(5):182-90. PubMed ID: 14603076
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.
Li MJ; Li Q; Sun M; Liu LQ
Medicine (Baltimore); 2017 Sep; 96(39):e8120. PubMed ID: 28953640
[TBL] [Abstract][Full Text] [Related]
3. Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline.
Dilger K; Zheng Z; Klotz U
Br J Clin Pharmacol; 1999 Sep; 48(3):438-44. PubMed ID: 10510158
[TBL] [Abstract][Full Text] [Related]
4. Greenness-sustainability metrics for assessment smart-chemometric spectrophotometric strategy for evaluation of the combination of six gastric proton-pump inhibitors with two selected impurities.
Amin KFM
MethodsX; 2024 Jun; 12():102670. PubMed ID: 38577411
[TBL] [Abstract][Full Text] [Related]
5. Anti-inflammatory and anti-oxidative properties of proton pump inhibitors.
Naito Y
J Clin Biochem Nutr; 2007 Sep; 41(2):82-3. PubMed ID: 18193100
[No Abstract] [Full Text] [Related]
6. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.
Freedberg DE; Kim LS; Yang YX
Gastroenterology; 2017 Mar; 152(4):706-715. PubMed ID: 28257716
[TBL] [Abstract][Full Text] [Related]
7. Patient-centered Outcomes with Concomitant Use of Proton Pump Inhibitors and Other Drugs.
Shamliyan TA; Middleton M; Borst C
Clin Ther; 2017 Feb; 39(2):404-427.e36. PubMed ID: 28189362
[TBL] [Abstract][Full Text] [Related]
8. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Miner P; Katz PO; Chen Y; Sostek M
Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
[TBL] [Abstract][Full Text] [Related]
9. Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study.
Moberg LM; Nilsson PM; Samsioe G; Borgfeldt C
Maturitas; 2014 Aug; 78(4):310-5. PubMed ID: 24958166
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update.
Wedemeyer RS; Blume H
Drug Saf; 2014 Apr; 37(4):201-11. PubMed ID: 24550106
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Interventions to Deprescribe Inappropriate Proton Pump Inhibitors in Older Adults.
Wilsdon TD; Hendrix I; Thynne TR; Mangoni AA
Drugs Aging; 2017 Apr; 34(4):265-287. PubMed ID: 28220380
[TBL] [Abstract][Full Text] [Related]
12. Practical considerations in the management of proton-pump inhibitors.
Aguilera-Castro L; Martín-de-Argila-dePrados C; Albillos-Martínez A
Rev Esp Enferm Dig; 2016 Mar; 108(3):145-53. PubMed ID: 26666270
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors.
Shin JM; Kim N
J Neurogastroenterol Motil; 2013 Jan; 19(1):25-35. PubMed ID: 23350044
[TBL] [Abstract][Full Text] [Related]
14. Proton pump inhibitor for non-erosive reflux disease: a meta-analysis.
Zhang JX; Ji MY; Song J; Lei HB; Qiu S; Wang J; Ai MH; Wang J; Lv XG; Yang ZR; Dong WG
World J Gastroenterol; 2013 Dec; 19(45):8408-19. PubMed ID: 24363534
[TBL] [Abstract][Full Text] [Related]
15. Proton pump inhibitors in pediatrics : mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics.
Ward RM; Kearns GL
Paediatr Drugs; 2013 Apr; 15(2):119-31. PubMed ID: 23512128
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
Çelebi A; Aydın D; Kocaman O; Konduk BT; Şentürk Ö; Hülagü S
Turk J Gastroenterol; 2016 Sep; 27(5):408-414. PubMed ID: 27782887
[TBL] [Abstract][Full Text] [Related]
17. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Li XQ; Andersson TB; Ahlström M; Weidolf L
Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
[TBL] [Abstract][Full Text] [Related]
18. Proton pump inhibitors: an update of their clinical use and pharmacokinetics.
Shi S; Klotz U
Eur J Clin Pharmacol; 2008 Oct; 64(10):935-51. PubMed ID: 18679668
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
